At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Daniel Keizman, MD, of Tel-Aviv Sourasky Medical Center, showcases his research on the Decipher genomic classifier of early prostate cancer, and underlying transcriptomic profiles for American versus non-American populations. He elaborates on the key differences in the transcriptomic profiles observed between these populations, as well as how these differences may influence the clinical utility of Decipher in diverse patient populations. ...
Localized Prostate Cancer
Advertisement
Latest News
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
The study found promising results with lenvatinib + belzutifan for patients with previously treated RCC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.